Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

ADF Wars: PTIE's Remoxy "passes" HAL study


http://ih.advfn.com/p.php?pid=nmona&article=66823818

This study demonstrated with statistical significance (p<0.0001) that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High.

On the co-primary endpoint of Drug Liking, scores were significantly lower for intact REMOXY (p<0.0001) and for chewed REMOXY (p<0.0001) compared to IR oxycodone.
On the co-primary endpoint of Drug High, scores were significantly lower for intact REMOXY (p<0.0001) and for chewed REMOXY (p<0.0001) compared to IR oxycodone.

PTIE's keyboard must be broken. Where are the numbers? Reporting top-line data without actually giving any data is strongly suggestive that while the results may have been "statistically significant" they probably were not very impressive. This is like telling your wife she looks "nice" on your wedding day. "Honey, your beauty is statistically significant."


This is an excellent opportunity for those of you feeling a sad about your ELTP investment to do a comparison. Look at PTIE. This is all they have. Their ADF is not modular, and any future ADF development will start from scratch. They've been kicking this can down the road for as long as Elite, including a rejection from a Big Pharma (Pfizer). Give them credit for taking it back and continuing with development on their own, but they've got nothing else- no generics, no ADF pipeline.

Now look at Elite's ELI-200 HAL data PR:


http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=74674&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

The study results demonstrated statistically significant (p <.0001) lower measures of drug liking, drug high and good drug effects for Elite’s manipulated (crushed) ELI-200 when compared to the manipulated (crushed) drug listed comparator product and found 91.9% of the subjects experienced increased drug liking with the comparator product compared to ELI-200 in non-dependent recreational drug users when administered intranasally. The study also found 80.6% of the subjects experienced a decrease in drug liking with the intranasal crushed ELI-200 in comparison to the administration of oral intact ELI-200.

That, my friends, is how you report top-line HAL data. And Elite's 2 bead modular pharm-based ADF will demonstrate equally awesome HAL data across a broad range of ADF opioid agonists and time-release characteristics. In the ADF Wars, Elite is a Superpower, and PTIE is a mercenary in a broken down truck.